Интенсивный контроль артериального давления: возможности комбинированной фармакотерапии

артериальное давление, комбинированная антигипертензивная терапия

1. Davis BR, Cutler JA et al. Rationale and design for the Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996; 9: 342-60.

2. SHEP Co-operative research group prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991; 265: 3255-64.

3. Pepine CJ et al. INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronaryartery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290 (21): 2805-16.

4. Danhlo..f B, Gosse P. on behalf of the PICXEL investigators. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens 2005; 11: 2063-70.

5. Danhlo..f B et al. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.

6. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertensive Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-62.

7. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and micro vascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13.

8. Диагностика и лечение артериальной гипертензии. Российские рекомендации (3-й пересмотр), М., 2008.

9. Беленков Ю.Н. и рабочая группа исследования ЭПИГРАФ-2: Агеев Ф.Т., Бойцов С.А., Лазебник Л.Б., Мареев В.Ю., Оганов Р.Г., Ольбинская Л.И., Обренович-Кирчански Б., Остоич М., Поздняков Ю.М., Чазова И.Е., Шляхто Е.В. Эналаприл Плюс Индапамид в лечении артериальной Гипертонии: оценка эффективности и безопасности РАциональной Фармакотерапии. Применение нефиксированной комбинации эналаприла и индапамида (Энзикс). Дизайн и основные результаты исследования ЭПИГРАФ - 2. Сердце. 2005; 4 (5): 98-103.

10. Беленков Ю.Н., Мареев В.Ю. от имени рабочей группы исследования ЭПИГРАФ. Эналаприл Плюс Индапамид в лечении стабильной артериальной Гипертонии: оценка эффективности и безопасности РАциональной комбинированной Фармакотерапии (ЭПИГРАФ). Первые результаты Российского многоцентрового исследования ЭПИГРАФ-1. Сердце. 2003; 2 (4): 3-7.

11. Мартынюк Т.В., Колос И.П., Чазова И.Е. от имени соисследователей программы СТРАТЕГИЯ. Эффективность и безопасность фиксированной комбинации малых доз периндоприла/индапамида у пациентов с артериальной гипертонией в условиях реальной практической практики. Кардиоваскул. тер. и профилак. 2007; 6 (8): 21-7.

12. Ruilope L, Zanchetti A. Targeting hypertension with valsartan: Lessons learned from the valsartan/HCTZ versus amlodipine in stage II hypertensive patients (VAST) trial J of the renin-angiotensin-aldosterone system 2006; 7: S1 [Note(s): S8-11.

13. Mogensen CE et al. Effect of a low dose Perindopril/indapamide on albuminuria in diabetes. Preterax in albuminuria regression: PREMIER. Hypertension 2003; 41: 1063-71.

14. PROGRESS collaborative group. Randomised trial of perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358: 1033-41.

15. Mourad JJ et al. What rates of blood pressure normalisation can be expected from a first-line combination therapy in the real life? The OPTIMAX study. Eur Heart J 2006; 27(suppl.): 298. (Abstr 1792).

16. De Luca N et al. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study. Am J Hypertens 2004; 8: 660-7.

17. Danhlo..f B et al. for the ASCOT investigators/Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumetiazide as required, in the anglo-Scandinavian cardiac outcomes trial blood pressure lowering arm: a multicentre randomized controlled trial. Lancet 2005; 366: 895-906.

18. Mourad JJ et al. on behalf of the investigators of the STRATHE trial. Comparision of different therapeutic strategies in hypertension: a low-dose combination of low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped care approach. J Hypertens 2004; 22: 2379-96.

19. Advance Collaborative group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomesin patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007; 370: 829-40.

20. Kjeldsen SE et al. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. Blood Press 2008; 17 (1): 7-17.

21. Scholze J et al. Optimal treatment of obesity-related hypertension: The hypertension-obesity-sibutramine (HOS) study. Circulation 2007; 115 (15): 1991-8.

22. Ruggenenti P et al. Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-51.

23. Lindholm LH et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21 (8): 1563-74.

24. Mogensen CE et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Brit Med J 2000; 321: 1440-4.

25. Dogrell SA. ACE inhibitors and AT-1-receptor antagonists COOPERATE in non-diabetic renal disease. Lancet 2003; 361: 117-24.

26. Joshi SR et al. Evaluation of efficacy and tolerability of Losartan and Ramipril combination in the management of hypertensive patients with associated diabetes mellitus in India (LORD Trial). J Assoc Physicians India 2004; 52: 189-95.

27. Yusuf S et al. for the ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59.

28. Frishman WN et al. A multifactorial trial desigh to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide. Arch Intern Med 1994; 154: 1461-8.